Effect of benzyl alcohol on recombinant human interleukin-1 receptor antagonist structure and hydrogen-deuterium exchange

Journal of Pharmaceutical Sciences

Volumn 100, Issue 10, 2011, Pages 4215-4224

  Alford, John R ^a   Fowler, Andrew C ^b   Wuttke, Deborah S ^b   Kerwin, Bruce A ^c   Latypov, Ramil F ^c   Carpenter, John F ^d   Randolph, Theodore W ^a  

^a UCB 450   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c AMGEN INC   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

Excipients; NMR spectroscopy; Protein aggregation; Protein formulation; Protein structure

Indexed keywords

BENZYL ALCOHOL; CITRATE SODIUM; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SODIUM CHLORIDE; SOLVENT; IL1RN PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PRESERVATIVE; PROTEIN AGGREGATE; PROTEIN BINDING; RECOMBINANT PROTEIN;

ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; DEUTERIUM HYDROGEN EXCHANGE; HUMAN; HYDROPHOBICITY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEAR OVERHAUSER EFFECT; PROTEIN AGGREGATION; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; MEDICINAL CHEMISTRY; METABOLISM; PHARMACEUTICS; PROCEDURES; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION; TEMPERATURE;

BENZYL ALCOHOL; BINDING SITES; CHEMISTRY, PHARMACEUTICAL; DEUTERIUM EXCHANGE MEASUREMENT; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; PRESERVATIVES, PHARMACEUTICAL; PROTEIN AGGREGATES; PROTEIN BINDING; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE;

EID: 80052263952     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22601     Document Type: Article

References (45)

1. Tan EL, Shah HS, Leister KJ, Kozick LM, Pasciak P, Vanderlaan RK, Yu CD, Patel B. 1993. Transforming growth factor-alpha (TGF-alpha) in a semisolid dosage form: Preservative and vehicle selection. Pharm Res 10(8):1238-1242.
2. Batorova A, Martinowitz U. 2002. Continuous infusion of coagulation factors. Haemophilia 8(3):170-177.
3. Belgaumi AF, Patrick CC, Deitcher SR. 1999. Stability and sterility of a recombinant factor VIII concentrate prepared for continuous infusion administration. Am J Hematol 62(1):13-18.
4. Jorgensen JT, Mortensen HB, Jorgensen JOL. 1991. Patient acceptance of Nordiject: A new drug delivery system for growth-hormone. DICP 25(6):585-588.
5. Akers MJ, Boand AV, Binkley DA. 1984. Preformulation method for parenteral preservative efficacy evaluation. J Pharm Sci 73(7):903-905.
6. Maa YF, Hsu CC. 1996. Aggregation of recombinant human growth hormone induced by phenolic compounds. Int J Pharm 140(2):155-168.
7. Lam XM, Patapoff TW, Nguyen TH. 1997. The effect of benzyl alcohol on recombinant human interferon-gamma. Pharm Res 14(6):725-729.
8. Gupta S, Kaisheva E. 2003. Development of a multidose formulation for a humanized monoclonal antibody using experimental design techniques. AAPS PharmSci 5(2):E8.
9. Rodrigues-Silva R, Antunes GF, Velarde DT, Santoro MM. 1999. Thermal stability studies of hyperimmune horse antivenoms. Toxicon 37(1):33-45.
10. Remmele RL, Nightlinger NS, Srinivasan S, Gombotz WR. 1998. Interleukin-1 receptor (IL-1R) liquid formulation development using differential scanning calorimetry. Pharm Res 15(2):200-208.
11. Fransson J, Hallen D, FlorinRobertsson E. 1997. Solvent effects on the solubility and physical stability of human insulin-like growth factor I. Pharm Res 14(5):606-612.
12. Runkel L, Meier W, Pepinsky RB, Karpusas M, Whitty A, Kimball K, Brickelmaier M, Muldowney C, Jones W, Goelz SE. 1998. Structural and functional differences between glycosylated and nonglycosylated forms of human interferon-beta (IFN-beta). Pharm Res 15(4):641-649.
13. Townsend MW, Deluca PP. 1990. Stability of ribonuclease A in solution and the freeze-dried state. J Pharm Sci 79(12):1083-1086.
14. Schellekens H. 2002. Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clin Ther 24(11):1720-1740.
15. Schellekens H. 2002. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 1(6):457-462.
16. Yon JM. 1996. The specificity of protein aggregation. Nat Biotechnol 14(10):1231-1231.
17. Nair B. 2001. Final report on the safety assessment of benzyl alcohol, benzoic acid, and sodium benzoate. Int J Toxicol 20:23-50.
18. Tobler SA, Holmes BW, Cromwell ME, Fernandez EJ. 2004. Benzyl alcohol-induced destabilization of interferon-gamma: A study by hydrogen-deuterium isotope exchange. J Pharm Sci 93(6):1605-1617.
19. Zhang Y, Roy S, Jones LS, Krishnan S, Kerwin BA, Chang BS, Manning MC, Randolph TW, Carpenter JF. 2004. Mechanism for benzyl alcohol-induced aggregation of recombinant human interleukin-1 receptor antagonist in aqueous solution. J Pharm Sci 93(12):3076-3089.
20. Roy S, Jung R, Kerwin BA, Randolph TW, Carpenter JF. 2005. Effects of benzyl alcohol on aggregation of recombinant human interleukin-1-receptor antagonist in reconstituted lyophilized formulations. J Pharm Sci 94(2):382-396.
21. Chi EY, Kendrick BS, Carpenter JF, Randolph TW. 2005. Population balance modeling of aggregation kinetics of recombinant human interleukin-1 receptor antagonist. J Pharm Sci 94(12):2735-2748.
22. Ragone R, Colonna G, Balestrieri C, Servillo L, Irace G. 1984. Determination of tyrosine exposure in proteins by second-derivative spectroscopy. Biochemistry 23(8):1871-1875.
23. Liu K, Cho HS, Hoyt DW, Nguyen TN, Olds P, Kelly JW, Wemmer DE. 2000. Deuterium-proton exchange on the native wild-type transthyretin tetramer identifies the stable core of the individual subunits and indicates mobility at the subunit interface. J Mol Biol 303(4):555-565.
24. Olofsson A, Ippel JH, Wijmenga SS, Lundgren E, Ohman A. 2004. Probing solvent accessibility of transthyretin amyloid by solution NMR spectroscopy. J Biol Chem 279(7):5699-5707.
25. Ippel JH, Olofsson A, Schleucher J, Lundgren E, Wijmenga SS. 2002. Probing solvent accessibility of amyloid fibrils by solution NMR spectroscopy. Proc Natl Acad Sci U S A 99(13):8648-8653.
26. Olofsson A, Sauer-Eriksson AE, Ohman A. 2006. The solvent protection of alzheimer amyloid-beta-(1-42) fibrils as determined by solution NMR spectroscopy. J Biol Chem 281(1):477-483.
27. Whittemore NA, Mishra R, Kheterpal I, Williams AD, Wetzel R, Serpersu EH. 2005. Hydrogen-deuterium (H/D) exchange mapping of Abeta 1-40 amyloid fibril secondary structure using nuclear magnetic resonance spectroscopy. Biochemistry 44(11):4434-4441.
28. Yamaguchi KI, Katou H, Hoshino M, Hasegawa K, Naiki H, Goto Y. 2004. Core and heterogeneity of beta2-microglobulin amyloid fibrils as revealed by H/D exchange. J Mol Biol 338(3):559-571.
29. Hoshino M, Katou H, Hagihara Y, Hasegawa K, Naiki H, Goto Y. 2002. Mapping the core of the beta(2)-microglobulin amyloid fibril by H/D exchange. Nat Struct Biol 9(5):332-336.
30. Latypov RF, Liu D, Gunasekaran K, Harvey TS, Razinkov VI, Raibekas AA. 2008. Structural and thermodynamic effects of ANS binding to human interleukin-1 receptor antagonist. Protein Sci 17(4):652-663.
31. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. 1995. NMRPipe: A multidimensional spectral processing system based on UNIX pipes. J Biomol NMR 6(3):277-293.
32. Goddard TD, Kneller DG. 1977. Sparky 3: NMR assignment and integration software. San Franciso: University of California.
33. Stockman BJ, Scahill TA, Roy M, Ulrich EL, Strakalaitis NA, Brunner DP, Yem AW, Deibel MR Jr. 1992. Secondary structure and topology of interleukin-1 receptor antagonist protein determined by heteronuclear three-dimensional NMR spectroscopy. Biochemistry 31(23):5237-5245.
34. Orbons LPM, van der Marel GA, van Boom JH, Altona C. 1987. An NMR study of polymorphous behaviour of the mismatched DNA octamer d(m5C-G-m5C-G-A-G-m5C-G) in solution. Eur J Biochem 170:225-239.
35. Markley JL, Bax A, Arata Y, Hilbers CW, Kaptein R, Sykes BD, Wright PE, Wüthrich K. 1998. Recommendations for the presentation of NMR structures of proteins and nucleic acids. J Mol Biol 280(5):933-952.
36. Farmer BT II, Constantine KL, Goldfarb V, Friedrichs MS, Wittekind M, Yanchunas J Jr., Robertson JG, Mueller L. 1996. Localizing the NADP+ binding site on the MurB enzyme by NMR. Nat Struct Biol 3(12):995-997.
37. Bai YW, Milne JS, Mayne L, Englander SW. 1993. Primary structure effects on peptide group hydrogen exchange. Proteins 17(1):75-86.
38. Palmer AG, Rance M, Wright PE. 1991. Intramolecular motions of a zinc finger DNA-binding domain from Xfin characterized by proton-detected natural abundance carbon-12 heteronuclear NMR spectroscopy. J Am Chem Soc 113(12):4371-4380.
39. Kendrick BS, Chang BS, Arakawa T, Peterson B, Randolph TW, Manning MC, Carpenter JF. 1997. Preferential exclusion of sucrose from recombinant interleukin- 1 receptor antagonist: Role in restricted conformational mobility and compaction of native state. Proc Natl Acad Sci U S A 94(22):11917-11922.
40. Roy S, Katayama D, Dong A, Kerwin BA, Randolph TW, Carpenter JF. 2006. Temperature dependence of benzyl alcohol- and 8-anilinonaphthalene-1-sulfonate-induced aggregation of recombinant human interleukin-1 receptor antagonist. Biochemistry 45(12):3898-3911.
41. Kyte J, Doolittle RF. 1982. A simple method for displaying the hydropathic character of a protein. J Mol Biol 157(1):105-132.
42. Raibekas AA, Bures EJ, Siska CC, Kohno T, Latypov RF, Kerwin BA. 2005. Anion binding and controlled aggregation of human interleukin-1 receptor antagonist. Biochemistry 44(29):9871-9879.
43. Alford JR, Kwok SC, Roberts JN, Wuttke DS, Kendrick BS, Carpenter JF, Randolph TW. 2008. High concentration formulations of recombinant human interleukin-1 receptor antagonist: I. Physical characterization. J Pharm Sci 97(8):3035-3050.
44. Alford JR, Kendrick BS, Carpenter JF, Randolph TW. 2007. High concentration formulations of recombinant human interleukin-1 receptor antagonist: II. Aggregation kinetics. J Pharm Sci 97(8):3005-3021.
45. Thirumangalathu R, Krishnan S, Brems DN, Randolph TW, Carpenter JF. 2006. Effects of pH, temperature, and sucrose on benzyl alcohol-induced aggregation of recombinant human granulocyte colony stimulating factor. J Pharm Sci 95(7):1480-1497.